{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:45:52Z","timestamp":1761965152788,"version":"3.37.3"},"reference-count":14,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,2,11]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Targeted RNA sequencing detected a cryptic G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia and normal FISH studies. Consistent with the patient\u2019s response to imatinib, we demonstrate this rearrangement is oncogenic and sensitive to TKI in cell culture.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019001182","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T11:39:55Z","timestamp":1580384395000},"page":"445-448","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia"],"prefix":"10.1182","volume":"4","author":[{"given":"Max","family":"Jan","sequence":"first","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital, Boston, MA;"},{"name":"Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel E.","family":"Grinshpun","sequence":"additional","affiliation":[{"name":"Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA;"},{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9230-8747","authenticated-orcid":false,"given":"Julian A.","family":"Villalba","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Dal Cin","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Harvard University, Boston, MA;"},{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9788-0221","authenticated-orcid":false,"given":"David B.","family":"Sykes","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Harvard University, Boston, MA;"},{"name":"Division of Hematology, Massachusetts General Hospital Cancer Center, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. John","family":"Iafrate","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital, Boston, MA;"},{"name":"Harvard Medical School, Harvard University, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin L.","family":"Ebert","sequence":"additional","affiliation":[{"name":"Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA;"},{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Harvard Medical School, Harvard University, Boston, MA;"},{"name":"Howard Hughes Medical Institute, Dana-Farber Cancer Institute, Boston, MA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0199-9333","authenticated-orcid":false,"given":"Gabriela S.","family":"Hobbs","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Harvard University, Boston, MA;"},{"name":"Division of Hematology\/Oncology, Massachusetts General Hospital, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Nardi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital, Boston, MA;"},{"name":"Harvard Medical School, Harvard University, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2020,1,30]]},"reference":[{"issue":"6","key":"2020021111262489900_B1","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/blood-2016-10-695973","article-title":"Myeloid neoplasms with eosinophilia","volume":"129","author":"Reiter","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2020021111262489900_B2","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00277-017-3067-x","article-title":"Imatinib in myeloid\/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase","volume":"96","author":"Jawhar","year":"2017","journal-title":"Ann Hematol"},{"issue":"2","key":"2020021111262489900_B3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0092-8674(94)90322-0","article-title":"Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation","volume":"77","author":"Golub","year":"1994","journal-title":"Cell"},{"issue":"1","key":"2020021111262489900_B4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2141.1987.tb02291.x","article-title":"Abnormalities of chromosome 12p13 and malignant proliferation of eosinophils: a nonrandom association","volume":"67","author":"Keene","year":"1987","journal-title":"Br J Haematol"},{"issue":"12","key":"2020021111262489900_B5","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1182\/blood.V90.12.4947","article-title":"CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins","volume":"90","author":"Carroll","year":"1997","journal-title":"Blood"},{"issue":"23","key":"2020021111262489900_B6","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1182\/blood-2014-02-555607","article-title":"Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib","volume":"123","author":"Cheah","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2020021111262489900_B7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000046641","article-title":"Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor beta","volume":"107","author":"Steer","year":"2002","journal-title":"Acta Haematol"},{"issue":"12","key":"2020021111262489900_B8","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/nm.3729","article-title":"Anchored multiplex PCR for targeted next-generation sequencing","volume":"20","author":"Zheng","year":"2014","journal-title":"Nat Med"},{"issue":"5094","key":"2020021111262489900_B9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1126\/science.7678707","article-title":"Identification of the SH3 domain of GAP as an essential sequence for Ras-GAP-mediated signaling","volume":"259","author":"Duchesne","year":"1993","journal-title":"Science"},{"issue":"5","key":"2020021111262489900_B10","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41419-018-0504-2","article-title":"G3BP1 promotes tumor progression and metastasis through IL-6\/G3BP1\/STAT3 signaling axis in renal cell carcinomas","volume":"9","author":"Wang","year":"2018","journal-title":"Cell Death Dis"},{"issue":"1","key":"2020021111262489900_B11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.celrep.2018.03.050","article-title":"Driver fusions and their implications in the development and treatment of human cancers","volume":"23","author":"Gao","year":"2018","journal-title":"Cell Rep"},{"issue":"7","key":"2020021111262489900_B12","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta","volume":"347","author":"Apperley","year":"2002","journal-title":"N Engl J Med"},{"issue":"9","key":"2020021111262489900_B13","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3324\/haematol.11420","article-title":"The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study","volume":"92","author":"Baccarani","year":"2007","journal-title":"Haematologica"},{"issue":"22","key":"2020021111262489900_B14","doi-asserted-by":"crossref","first-page":"33229","DOI":"10.18632\/oncotarget.8906","article-title":"Long-term outcomes of imatinib in patients with FIP1L1\/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China","volume":"7","author":"Qu","year":"2016","journal-title":"Oncotarget"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/3\/445\/1634288\/advancesadv2019001182.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/3\/445\/1634288\/advancesadv2019001182.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T11:27:49Z","timestamp":1581420469000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/3\/445\/440966\/A-cryptic-imatinibsensitive-G3BP1PDGFRB"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,30]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,2,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019001182","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published":{"date-parts":[[2020,1,30]]}}}